Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of Bloomberg report, citing people familiar with the matter. The news removes some of the pressure on Pfizer CEO Albert Bourla, but Starboard, which took a $1B stake in the company late last year, could still propose changes to the board in 2026 if the two sides don’t reach a settlement before then, Bloomberg says.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer (PFE) Pays $59.7 Million Fine to Resolve Charges in Kickback Scheme
- Pfizer to pay ~$60M to settle Medicare false claims
- Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies
- Morgan Stanley Backs Chipmaker Qorvo after Starboard Stake
- Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards